Humacyte initiated with bullish view at H.C. Wainwright, here’s why

H.C. Wainwright initiated coverage of Humacyte with a Buy rating and $6 price target. Humacyte is a late clinical-stage regenerative medicine company creating universally implantable bioengineered human tissues, the analyst tells investors in a research note. The firm says the company’s lead asset, human acellular vessel, a sterile, acellular tubular graft composed of human collagen and other natural extracellular matrix proteins, represents a promising alternative to synthetic materials and autologous grafts used in the treatment of trauma and methods for hemodialysis arteriovenous access.